Johnson & Johnson (NYSE:JNJ) had its target price increased by equities research analysts at Credit Suisse Group from $151.00 to $152.00 in a research note issued to investors on Wednesday, BenzingaRatingsTable reports. The firm currently has an “outperform” rating on the stock. Credit Suisse Group’s target price points to a potential upside of 10.23% from the company’s current price.
JNJ has been the subject of several other research reports. Raymond James lifted their price objective on shares of Johnson & Johnson from $145.00 to $147.00 and gave the company an “outperform” rating in a research note on Wednesday. Morgan Stanley lifted their price objective on shares of Johnson & Johnson from $134.00 to $145.00 and gave the stock an “equal weight” rating in a report on Wednesday. Zacks Investment Research raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $155.00 price objective on the stock in a report on Wednesday, March 27th. Barclays reissued an “equal weight” rating and issued a $135.00 price target (down from $137.00) on shares of Johnson & Johnson in a report on Wednesday, January 23rd. Finally, Citigroup boosted their price objective on Johnson & Johnson from $139.00 to $147.00 and gave the company a “neutral” rating in a research note on Monday, February 25th. Six investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $144.67.
NYSE:JNJ traded down $0.13 during mid-day trading on Wednesday, hitting $137.89. 1,734,327 shares of the company’s stock were exchanged, compared to its average volume of 5,437,931. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.47 and a quick ratio of 1.20. Johnson & Johnson has a fifty-two week low of $118.62 and a fifty-two week high of $148.99. The company has a market cap of $370.29 billion, a PE ratio of 16.86, a P/E/G ratio of 2.21 and a beta of 0.68.
Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, April 16th. The company reported $2.10 EPS for the quarter, topping the consensus estimate of $2.03 by $0.07. Johnson & Johnson had a net margin of 18.75% and a return on equity of 35.63%. The business had revenue of $20.02 billion for the quarter, compared to the consensus estimate of $19.55 billion. During the same period last year, the company earned $2.06 EPS. The firm’s revenue was up .1% compared to the same quarter last year. Equities research analysts expect that Johnson & Johnson will post 8.58 EPS for the current year.
Several hedge funds have recently bought and sold shares of the stock. Evolution Wealth Advisors LLC purchased a new stake in shares of Johnson & Johnson during the fourth quarter valued at approximately $40,000. Crewe Advisors LLC boosted its stake in shares of Johnson & Johnson by 75.0% during the fourth quarter. Crewe Advisors LLC now owns 350 shares of the company’s stock valued at $45,000 after purchasing an additional 150 shares during the period. Horan Securities Inc. boosted its stake in shares of Johnson & Johnson by 122.3% during the fourth quarter. Horan Securities Inc. now owns 438 shares of the company’s stock valued at $56,000 after purchasing an additional 241 shares during the period. First Bank & Trust boosted its stake in shares of Johnson & Johnson by 30.4% during the first quarter. First Bank & Trust now owns 399 shares of the company’s stock valued at $56,000 after purchasing an additional 93 shares during the period. Finally, Stone House Investment Management LLC purchased a new stake in shares of Johnson & Johnson during the first quarter valued at approximately $58,000. Institutional investors own 67.32% of the company’s stock.
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
See Also: What causes a recession?
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.